U.S. markets closed

AngioDynamics, Inc. (ANGO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
24.23+0.02 (+0.08%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close24.21
Open24.19
Bid24.18 x 800
Ask24.24 x 1200
Day's Range23.80 - 24.50
52 Week Range8.05 - 24.50
Volume155,309
Avg. Volume324,132
Market Cap924.069M
Beta (5Y Monthly)0.82
PE Ratio (TTM)N/A
EPS (TTM)-4.43
Earnings DateJul 14, 2021 - Jul 19, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est25.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • AngioDynamics Submits 510(K) Application For AlphaVac System
    SmarterAnalyst

    AngioDynamics Submits 510(K) Application For AlphaVac System

    Minimally invasive medical devices provider AngioDynamic Inc has submitted a 510(K) application for its AlphaVac System to the U.S. Food and Drug Administration (FDA). The Alphavac System is an off-circuit, multi-purpose mechanical aspiration thrombectomy device. It is designed to treat unwanted intravascular material in the venous system and peripheral vasculature. AngioDynamics (ANGO) President and Chief Executive Officer, Jim Clemmer, said, “We are excited to announce this important milestone in the ongoing transformation of our portfolio. Our team developed AlphaVac in collaboration with leading physicians to enable treatment in more cases without the need for perfusion while providing control, power, and versatility to drive positive patient outcomes.” Clemmer added, “AlphaVac expands our thrombus management portfolio allowing us to serve a larger, fast-growing segment of the thrombectomy market and we are confident it will become a go-to treatment option for physicians.” (See AngioDynamics stock analysis on TipRanks) The AlphaVac System makes use of the company’s two proprietary technologies, including a mechanical aspiration handle and a self-expanding funnel tip. The system is designed to offer precise control during clot removal while also reducing blood loss. Subject to regulatory clearance, the company expects to bring the system to market in 2H21. On April 8, Raymond James analyst Jayson Bedford gave the stock a Buy rating but did not assign any price target. After meetings with the company’s management, Bedford expects “the stock to rerate higher on increasing confidence in consensus estimates and the 510K filing for Angio’s new mechanical thrombectomy device that opens up a new market opportunity, with a long term tail.” The other analyst covering the stock, Canaccord Genuity’s William Plovanic, has a Hold rating on the stock with a $24 price target (1% upside potential). The two ratings add up to a Moderate Buy consensus rating, with an average analyst price target of $24. Shares have gained about 127% over the past year. Related News: Chicken Soup Snaps up Sonar’s Film and Television Assets; Shares Bounce 6.4% Hologic To Snap Up Mobidiag For $795M, Provide Growth Platform Johnson Controls Snaps Up Silent-Aire For $870M More recent articles from Smarter Analyst: Regeneron’s REGEN-COV Shown To Reduce COVID-19 Progression In Phase 3 Trial Monday’s Pre-Market: Here’s What You Need To Know Before The Market Opens Sanofi Snaps Up Tidal Therapeutics For $160M Microsoft Set To Acquire Nuance For $16B – Report

  • AngioDynamics Submits 510(k) Application to FDA for AlphaVac Mechanical Thrombectomy System
    Business Wire

    AngioDynamics Submits 510(k) Application to FDA for AlphaVac Mechanical Thrombectomy System

    AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology today announced that on April 9, 2021, it submitted a 510(k) application to the United States Food and Drug Administration (FDA) for the AlphaVac System, an off-circuit, multi-purpose mechanical aspiration thrombectomy device for the treatment of undesirable intravascular material in the venous system and peripheral vasculature.

  • AngioDynamics to Present at the Needham Virtual Healthcare Conference
    Business Wire

    AngioDynamics to Present at the Needham Virtual Healthcare Conference

    AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the Needham Virtual Healthcare Conference at 8:45 a.m. ET on Monday, April 12, 2021.